A Highly Responsive Pancreatic Ductal Adenocarcinoma with Liver Metastasis: A Rare Case Report

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164. doi:10.3322/caac.21601
   PubMed Web of Science ®Google Scholar
• Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):16425. doi:10.1038/s41598-020-73525-y
   PubMed Web of Science ®Google Scholar
• Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247(3):456–462. doi:10.1097/SLA.0b013e3181613142
   PubMed Web of Science ®Google Scholar
• Picozzi VJ, Oh SY, Edwards A, et al. Five-year actual overall survival in resected pancreatic cancer: a contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol. 2017;24(6):1722–1730. doi:10.1245/s10434-016-5716-z
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152(3 Suppl 1):S43–9. doi:10.1016/j.surg.2012.05.020
   PubMed Web of Science ®Google Scholar
• Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–1057. doi:10.1016/S0140-6736(04)15841-8
   PubMed Web of Science ®Google Scholar
• Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Current standards of surgery for pancreatic cancer. Br J Surg. 2004;91(11):1410–1427. doi:10.1002/bjs.4794
   PubMed Web of Science ®Google Scholar
• Network NCC. NCCN guidelines for treatment of cancer by site: pancreatic adenocarcinoma. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed November 26, 2019.
   Google Scholar
• Ueno H, Ioka T, Ikeda M, et al. Randomized Phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640–1648. doi:10.1200/jco.2012.43.3680
   PubMed Web of Science ®Google Scholar
• Okusaka T, Miyakawa H, Fujii H, et al. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. J Cancer Res Clin Oncol. 2017;143(6):1053–1059. doi:10.1007/s00432-017-2349-y
   PubMed Web of Science ®Google Scholar
• Maeda A, Boku N, Fukutomi A, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan adjuvant study group of pancreatic cancer (JASPAC-01). Jpn J Clin Oncol. 2008;38(3):227–229. doi:10.1093/jjco/hym178
   PubMed Web of Science ®Google Scholar
• Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a Phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–257. doi:10.1016/s0140-6736(16)30583-9
   PubMed Web of Science ®Google Scholar
• Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–1812. doi:10.1007/s11605-015-2890-4
   PubMed Web of Science ®Google Scholar
• Schwarz L, Vernerey D, Bachet JB, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, Phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer. 2018;18(1):762. doi:10.1186/s12885-018-4663-4
   PubMed Web of Science ®Google Scholar
• Tachezy M, Gebauer F, Petersen C, et al. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer. 2014;14(1):411. doi:10.1186/1471-2407-14-411
   PubMed Web of Science ®Google Scholar
• Chang JH, Jiang Y, Pillarisetty VG. Role of immune cells in pancreatic cancer from bench to clinical application: an updated review. Medicine. 2016;95(49):e5541. doi:10.1097/md.0000000000005541
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9(5):353–363. doi:10.1038/nri2545
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61. doi:10.1038/nm1523
   PubMed Web of Science ®Google Scholar
• Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol. 2012;9(3):292–300. doi:10.3109/1547691x.2011.642418
   PubMed Web of Science ®Google Scholar
• Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210–221. doi:10.1016/j.canlet.2018.01.050
   PubMed Web of Science ®Google Scholar
• Amin S, Baine M, Meza J, Lin C. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. BMC Cancer. 2020;20(1):538. doi:10.1186/s12885-020-07016-8
   PubMed Web of Science ®Google Scholar
• Walker J, Waters RA, Murray G, et al. Better off dead: suicidal thoughts in cancer patients. J Clin Oncol. 2008;26(29):4725–4730. doi:10.1200/jco.2007.11.8844
   PubMed Web of Science ®Google Scholar
• Deshields T, Tibbs T, Fan MY, Taylor M. Differences in patterns of depression after treatment for breast cancer. Psycho-Oncology. 2006;15(5):398–406. doi:10.1002/pon.962
   PubMed Web of Science ®Google Scholar
• Mackenzie L, Mansfield E, Herrmann A, Grady A, Evans TJ, Sanson-Fisher R. Perceived problems with involvement in decision making about breast cancer treatment and care: a cross-sectional study. Patient Educ Couns. 2020. doi:10.1016/j.pec.2020.08.044
   PubMed Web of Science ®Google Scholar
• Hung HY, Tseng YH, Chao HS, et al. Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. PLoS One. 2020;15(10):e0236503. doi:10.1371/journal.pone.0236503
   PubMed Web of Science ®Google Scholar
• Kowalczyk A, Jassem J. Multidisciplinary team care in advanced lung cancer. Transl Lung Cancer Res. 2020;9(4):1690–1698. doi:10.21037/tlcr.2019.11.33
   PubMed Web of Science ®Google Scholar